Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06733935 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
A Phase 1 study of Systemic Sclerosis and Idiopathic Inflammatory Myopathies, sponsored by Nkarta.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 13
- Study locations
NCT06733935: Recruiting Phase 1 study of Systemic Sclerosis and Idiopathic Inflammatory Myopathies, sponsored by Nkarta.
NCT06733935 is a Phase 1 study of Systemic Sclerosis and Idiopathic Inflammatory Myopathies that is actively recruiting participants, run by Nkarta. The registered enrollment target is 144 participants, below the 274-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (47% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06733935, a Phase 1 study of Systemic Sclerosis and Idiopathic Inflammatory Myopathies, is actively recruiting participants, sponsored by Nkarta.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
Primary Outcome
Incidence of DLTs will be evaluated
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG NKX019
Study Locations (13)
Florida
- Nkarta Investigational Site - Miami
- Nkarta Investigational Site - Plantation
New York
- Nkarta Investigational Site - Stony Brook
- Nkarta Investigational Site - Syracuse
Texas
- Nkarta Investigational Site - Dallas
- Nkarta Investigational Site - Houston
California
- Nkarta Investigational Site - Orange
Illinois
- Nkarta Investigational Site - Chicago
Kansas
- Nkarta Investigational Site - Fairway
Michigan
- Nkarta Investigational Site - Ann Arbor
Minnesota
- Nkarta Investigational Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
What NCT06733935 shows while recruiting
NCT06733935 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 274-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (47% lower).
The record links to 3 conditions, with Systemic Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06733935 lists 13 locations in 10 states (Florida, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT06733935 about?
NCT06733935 is a clinical study titled "A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)". This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
What is the current status of trial NCT06733935?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2024-11-04. Estimated completion is 2028-10.
What conditions does trial NCT06733935 study?
This clinical trial studies the following conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT06733935?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), NKX019 (DRUG).
Who is sponsoring clinical trial NCT06733935?
This trial is sponsored by Nkarta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06733935 being conducted?
This trial has 13 study locations across California, Florida, Illinois, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06733935's enrollment target sits among peer trials
144 6th of 26 higher than 21 of 26 other Systemic Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RECRUITING · Phase 1
-
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI